英语翻译Centocor,Inc.announced today that the U.S.Food and Drug Administration (FDA) has approved Remicade(R) (infliximab) for the treatment of adult patients with chronic severe (i.e.extensive and/or disabling) plaque psoriasis who are candidate

来源:学生作业帮助网 编辑:作业帮 时间:2024/04/29 02:01:53
英语翻译Centocor,Inc.announced today that the U.S.Food and Drug Administration (FDA) has approved Remicade(R) (infliximab) for the treatment of adult patients with chronic severe (i.e.extensive and/or disabling) plaque psoriasis who are candidate

英语翻译Centocor,Inc.announced today that the U.S.Food and Drug Administration (FDA) has approved Remicade(R) (infliximab) for the treatment of adult patients with chronic severe (i.e.extensive and/or disabling) plaque psoriasis who are candidate
英语翻译
Centocor,Inc.announced today that the U.S.Food and Drug Administration (FDA) has approved Remicade(R) (infliximab) for the treatment of adult patients with chronic severe (i.e.extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.The recommended dose is an infusion of 5 mg/kg followed by additional doses at two and six weeks after the first infusion and then every eight weeks thereafter.In the Phase 3 clinical trial EXPRESS,eight out of 10 patients receiving Remicade 5 mg/kg induction therapy achieved 75 percent improvement in psoriasis as measured by Psoriasis Area Severity Index (PASI 75) by week 10.Similar results were seen with EXPRESS II,the second Phase 3 study.These results were maintained by every eight-week Remicade 5 mg/kg maintenance infusions at six months.The majority of patients who continued on this regimen achieved PASI 75 at week 50,the last visit in both studies.More than 1200 patients participated in the two Phase 3 clinical trials.

英语翻译Centocor,Inc.announced today that the U.S.Food and Drug Administration (FDA) has approved Remicade(R) (infliximab) for the treatment of adult patients with chronic severe (i.e.extensive and/or disabling) plaque psoriasis who are candidate
Centocor,Inc.今天宣布了,美国粮食与药物管理局(粮食与药物管理局) 批准了Remicade(R) (infliximab) 为成人病人的治疗有是候选人为系统疗法的慢性严厉(即广泛并且/或者失去能力) 匾psoriasis 并且当其它系统疗法是医疗上较不适当的.被推荐的药量是5 mg/kg 的注入被另外的药量尔后跟随在二个和六个星期在第一注入以后和然后每八个星期.在阶段3 临床试验明确,八丧失10 名患者接受Remicade 5 mg/kg 归纳疗法依照由Psoriasis Area 严肃索引(PASI 75) 测量达到了百分之75 在psoriasis 的改善在星期10 以前.近似结果看了与明确II,第二项阶段3 研究.这些结果由每8 个星期的Remicade 维护了5 mg/kg 维护注入在六个月.继续在这养生之道的多数患者达到了PASI 75 在星期50,最后参观在两项研究中.超过1200 名患者参加了两相3 次临床试验.